Encapsulating Peritoneal Sclerosis 1. 2. 3.
Gandhi VC, Humayun HM, Ing TS, et al., Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients, Arch Intern Med, 1980;140(9):1201–3.
Honda K, Oda H, Pathology of encapsulating peritoneal sclerosis, Perit Dial Int, 2005;25(Suppl. 4):S19–29.
Kawaguchi Y, Kawanishi H, Mujais S, et al., Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis, Perit Dial Int, 2000;20(Suppl. 4):S43–55.
4. 5. 6. 7.
Korte MR, Boeschoten EW, Betjes MG, The Dutch EPS Registry: increasing the knowledge of encapsulating peritoneal sclerosis, Neth J Med, 2009;67(8):359–62.
Brown MC, Simpson K, Kerssens JJ, Mactier RA, Encapsulating peritoneal sclerosis in the new millennium: a national cohort study, Clin J Am Soc Nephrol, 2009;4(7):1222–9.
Kawanishi H, Kawaguchi Y, Fukui H, et al., Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study, Am J Kidney Dis, 2004;44(4):729–37.
Nomoto Y, Kawaguchi Y, Kubo H, et al., Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group, Am J Kidney Dis, 1996;28(3):420–7.
8. 9.
Rigby RJ, Hawley CM, Sclerosing peritonitis: the experience in Australia, Nephrol Dial Transplant, 1998;13(1):154–9.
Nakamoto H, Kawaguchi Y, Suzuki H, Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan, Adv Perit Dial, 2002;18:119–23.
10. Afthentopoulos IE, Passadakis P, Oreopoulos DG, Bargman J, Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center’s experience and review of the literature, Adv Ren Replace Ther, 1998;5(3):157–67.
11. Jenkins SB, Leng BL, Shortland JR, et al., Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period, Adv Perit Dial, 2001;17:191–5.
12. Wilms H, Steinhauer HB, Riede UN, Kirste G, [Sclerosing peritonitis following continuous ambulatory peritoneal dialysis], Chirurg, 1986;57(11):737–40.
13. Balasubramaniam G, Brown EA, Davenport A, et al., The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis, Nephrol Dial Transplant, 2009;24(10):3209–15.
14. Brown EA, Van BW, Finkelstein FO, et al., Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD, Perit Dial Int, 2009;29(6):595–600.
15. Kawaguchi Y, Saito A, Kawanishi H, et al., Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures, Perit Dial Int, 2005;25(Suppl. 4):S83–95.
16. Guest S, Hypothesis: gender and encapsulating peritoneal sclerosis, Perit Dial Int, 2009;29(5):489–91.
17. Lafrance JP, Letourneau I, Ouimet D, et al., Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy, Am J Kidney Dis, 2008;51(2):e7–10.
18. Thirunavukarasu T, Saxena R, Anijeet H, et al., Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature, Ren Fail, 2007;29(6):775–6.
19. Chalasani R, Marella P, Sclerosing encapsulating peritonitis in a 47-year-old woman, Kidney Int, 2006;70(10):1673.
20. Sachdev A, Usatoff V, Thaow C, Sclerosing encapsulating peritonitis and methotrexate, Aust N Z J Obstet Gynaecol, 2006;46(1):58–9.
21. Payne WG, Ko F, Anspaugh S, et al., Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma, Ann Plast Surg, 2006;56(3):301–5.
22. Liu L, Shi CX, Ghayur A, et al., Prolonged peritoneal gene expression using a helper-dependent adenovirus, Perit Dial Int, 2009;29(5):508–16.
23. Chin AI, Yeun JY, Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis, Am J Kidney Dis, 2006;47(4):697–712.
24. Fracasso A, Coli U, Landini S, et al., Peritoneal sclerosis. Role of plasticizers, ASAIO Trans, 1987;33(3):676–82.
25. Kawanishi H, Surgical treatment for encapsulating peritoneal sclerosis, Adv Perit Dial, 2002;18:139–43.
26. Dobbie JW, Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis, Perit Dial Int, 1992;12(1):14–27.
27. Garosi G, Different aspects of peritoneal damage: fibrosis and sclerosis, Contrib Nephrol, 2009;163:45–53.
28. Numata M, Nakayama M, Hosoya T, et al., Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients, Clin Nephrol, 2004;62(6):455–60.
29. Nakayama M, The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment, Perit Dial Int, 2005;25(Suppl. 4):S71–6.
30. Park SH, Kim YL, Lindholm B, Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment, Perit Dial Int, 2008;28(Suppl. 5):S21–8.
31. Yamamoto R, Otsuka Y, Nakayama M, et al., Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment, Clin Exp Nephrol, 2005;9(2):148–52.
32. Summers AM, Hoff CM, Topley N, How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis?, Perit Dial Int, 2008;28(Suppl. 5):S16–20.
33. Nakamoto H, Encapsulating peritoneal sclerosis—a clinician’s approach to diagnosis and medical treatment, Perit Dial Int, 2005;25(Suppl. 4):S30–38.
34. Yamamoto R, Nakayama M, Hasegawa T, et al., High- transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment, Adv Perit Dial, 2002;18:131–4.
35. Kawanishi H, Fujimori A, Tsuchida K, et al., Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan, Adv Perit Dial, 2005;21:134–8.
36. Tarzi RM, Lim A, Moser S, et al., Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis, Clin J Am Soc Nephrol, 2008;3(6):1702–10.
37. Vlijm A, Stoker J, Bipat S, et al., Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study, Perit Dial Int, 2009;29(5):517–22.
38. Yavuz K, Erden A, Ates K, Erden I, MR peritoneography in complications of continuous ambulatory peritoneal dialysis, Abdom Imaging, 2005;30(3):361–8.
39. Kuriyama S, Tomonari H, Corticosteroid therapy in encapsulating peritoneal sclerosis, Nephrol Dial Transplant, 2001;16(6):1304–5.
40. Imai H, Nakamoto H, Fucshima R, et al., Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis, Adv Perit Dial, 2002;18:124–30.
41. Eltoum MA, Wright S, Atchley J, Mason JC, Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen, Perit Dial Int, 2006;26(2):203–6.
42. Lo WK, Kawanishi H, Encapsulating peritoneal sclerosis— medical and surgical treatment, Perit Dial Int, 2009;29 (Suppl. 2):S211–14.
43. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R, Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone, Perit Dial Int, 2005;25(3):285–7.
44. Gupta S, Woodrow G, Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal
peritonitis with tamoxifen, Clin Nephrol, 2007;68(2):125–9.
45. Guest S, Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences, Perit Dial Int, 2009;29(3):252–5.
46. Allaria PM, Giangrande A, Gandini E, Pisoni IB, Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?, J Nephrol, 1999;12(6):395–7.
47. del PG, Bajo MA, Gil F, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes, Adv Perit Dial, 2003;19:32–5.
48. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S, Successful surgical management of encapsulating peritoneal sclerosis, Perit Dial Int, 2005;25(Suppl 4):S39–47.
49. Kawanishi H, Moriishi M, Ide K, Dohi K, Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis, Perit Dial Int, 2008;28(Suppl. 3):S205–10.
50. Kittur DS, Korpe SW, Raytch RE, Smith GW, Surgical aspects of sclerosing encapsulating peritonitis, Arch Surg, 1990;125(12):1626–8.
51. Kawanishi H, Ide K, Yamashita M, et al., Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis, Adv Perit Dial, 2008;24:51–5.
52. Fagugli RM, Selvi A, Quintaliani G, et al., Immunosuppressive treatment for sclerosing peritonitis, Nephrol Dial Transplant, 1999;14(5):1343–5.
53. Duman S, Bozkurt D, Sipahi S, et al., Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model, Adv Perit Dial, 2008;24:104–10.
54. Bozkurt D, Cetin P, Sipahi S, et al., The effects of renin– angiotensin system inhibition on regression of encapsulating peritoneal sclerosis, Perit Dial Int, 2008;28(Suppl. 5):S38–42.
55. Sawada T, Ishii Y, Nakajima I, et al., An experimental model of encapsulating peritoneal sclerosis, Perit Dial Int, 2009;29(Suppl. 2):S49–50.
56. Nakamoto H, Imai H, Fukushima R, et al., Role of the renin– angiotensin system in the pathogenesis of peritoneal fibrosis, Perit Dial Int, 2008;28(Suppl. 3):S83–7.
57. Korte MR, Yo M, Betjes MG, et al., Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation, Nephrol Dial Transplant, 2007;22(8):2412–4.
58. Fieren MW, Betjes MG, Korte MR, Boer WH, Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?, Perit Dial Int, 2007;27(6):619–24.
59. de Freitas DG, Augustine T, Brenchley PE, Encapsulating peritoneal sclerosis following renal transplantation—the UK experience, Am J Transplant, 2007; abstract.
60. Dejagere T, Evenepoel P, Claes K, et al., Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient, Am J Kidney Dis, 2005;45(2):e33–7.
61. Hendriks MP, de Sevaux RG, Hilbrands LB, Encapsulating peritoneal sclerosis in patients on peritoneal dialysis, Neth J Med, 2008;66(7):269–74.
62. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S, Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity, Kidney Int, 2002;62(6):2257–63.
63. van WR, Aten J, Hajji N, et al., Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat, Blood Purif, 2007;25(5–6):466–72.
64. Moriishi M, Kawanishi H, Kawai T, et al., Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis, Adv Perit Dial, 2002;18:149–53.
65. Hung KY, Huang JW, Chiang CK, Tsai TJ, Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies, Nephrol Dial Transplant, 2008;23(12):3831–40.
66. Nakayama M, Yamamoto H, Ikeda M, et al., Risk factors and preventive measures for encapsulating peritoneal sclerosis– Jikei experience 2002, Adv Perit Dial, 2002;18:144–8.
US NEPHROLOGY
75
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100